sk&f 104976 has been researched along with 25-hydroxycholesterol in 1 studies
| Studies (sk&f 104976) | Trials (sk&f 104976) | Recent Studies (post-2010) (sk&f 104976) | Studies (25-hydroxycholesterol) | Trials (25-hydroxycholesterol) | Recent Studies (post-2010) (25-hydroxycholesterol) |
|---|---|---|---|---|---|
| 10 | 0 | 1 | 853 | 3 | 243 |
| Protein | Taxonomy | sk&f 104976 (IC50) | 25-hydroxycholesterol (IC50) |
|---|---|---|---|
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Homo sapiens (human) | 0.3 | |
| Sterol regulatory element-binding protein 2 | Homo sapiens (human) | 0.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bentzen, C; Berkhout, TA; Jackson, B; Niesor, E; Patel, DD; Simon, HM; Suckling, KE | 1 |
1 other study(ies) available for sk&f 104976 and 25-hydroxycholesterol
| Article | Year |
|---|---|
The novel cholesterol-lowering drug SR-12813 inhibits cholesterol synthesis via an increased degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Topics: Acetates; Anticholesteremic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Line; Cholesterol; Diphosphonates; Humans; Hydroxycholesterols; Hydroxymethylglutaryl CoA Reductases; Kinetics; Lanosterol; Lipoproteins, LDL; Liver Neoplasms; Lovastatin; Receptors, LDL; RNA, Messenger; Transcription, Genetic; Tritium; Tumor Cells, Cultured | 1996 |